ABSTRACT

Gout, the most common inflammatory arthritis is associated with a persistently raised plasma uric acid concentration. When these levels rise above the solubility limit it results in crystal deposition in joints, acute inflammation in response to those crystals causes severe pain. Treatment for severe gout includes injection of non-human uricase and anti-hyperuricemic and anti-inflammatory agents to reduce uric acid levels and inflammation. In the present study, the anti-inflammatory and the antihyperuricemic activity of the uricase produced by Bacillus subtilis MM13, isolated from poultry soil was evaluated in LPS-induced RAW 264.7 cells. To measure the effects of the uricase produced by Bacillus subtilis MM13, MTT assay, Trypan blue assay, xanthine oxidase activity assay, uric acid production and Gene expression analysis were performed. MTT and trypan blue assay demonstrated that uricase suppressed cell proliferation in a dose-dependent manner. The in vitro anti-hyperuricemic effect of uricase was identified due to the inhibition of Xanthine oxidase in LPS-induced RAW cells. Gene expression studies showed that Uricase suppressed the expression of inflammatory cytokine, tumour necrosis factor ? (TNF- ?), and increased production of IL-10, a potent inhibitor of TNF- ?. Considering the appreciable in vitro anti-hyperuricemic and anti-inflammatory activities, it is proposed that this preparation can be further studied for safety and efficacy under in vivo conditions which can be subsequently used for the prophylactic treatment of gout. Keywords: Uricase, hyperuricemic, MTT assay, Trypan blue assay, prophylaxis
Publication date: 15/01/2022

https://ijbpas.com/pdf/2022/January/MS_IJBPAS_2022_JAN_SPCL_1021.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.1.1021